Zdrowotne właściwości zachowań ruchowych – wybrane zagadnienia

Przyjmuje się, iż zachowania ruchowe człowieka mają wpływ na jego zdrowie i poprawiają sprawność fizyczną oraz usprawniają całokształt reakcji chemicznych i związanych z nimi przemian energii zachodzących w żywych komórkach generując wyzwania badawcze dla wielu dziedzin nauki. Zainteresowania autorów budzi rosnący ruch Nordic walking jako układ imprez masowych i jego pozytywny wpływ na metabolizm żelaza w organizmie jednostki

ОЗДОРОВЧІ ВЛАСТИВОСТІ РУХОВОЇ ПОВЕДІНКИ НА ПРИКЛАДІ СКАНДИНАВСЬКОЇ ХОДЬБИ ТА МЕТАБОЛІЗМУ ЗАЛІЗА

Вважається, що рухова поведінка людини впливає на її здоров’я та покращує фізичну форму, покращує загальні хімічні реакції та пов’язані з ними енергетичні зміни, які відбуваються в живих клітинах, генеруючи дослідницькі виклики для багатьох галузей науки. Зацікавленість авторів збуджує зростаючий рух скандинавської ходьби як системи масових подій і її позитивний вплив на метаболізм заліза в організмі людини

ПОШКОДЖЕННЯ ПІД ЧАС СПОРТИВНОГО ПЛАВАННЯ ТА ЇХ РЕАБІЛІТАЦІЯ

Ця стаття містить дані, пов’язані з плаванням, реабілітацією в спорті, лікуванням травм та запобіганням неналежному тренінгу. Питання, що є частиною цієї дисципліни, представлені та обговорюються. Плавання та реабілітація тісно пов’язані один з одним через часте перевантаження, пошкодження та травми, викликані тренуванням або неправильним вибором обладнання

Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials

Introduction: The safety and actions of mineralocorticoid receptor antagonists on surrogate markers of cardiovascular disease as well as major patient level cardiovascular end-points in patients with chronic kidney disease are unclear. Methods: MEDLINE, EMBASE, Trip Database, Cochrane Central Register of Controlled Trials, Cochrane Renal Group specialized register, Current Controlled Trials and clinicaltrials.gov were searched for relevant trials. Results: Twenty-nine trials (1581 patients) were included. Overall, mineralocorticoid receptor antagonists lowered both systolic and diastolic blood pressure (–5.24, 95% confidence interval (CI) –8.65, −1.82 mmHg; p=0.003 and −1.96, 95% CI −3.22, –0.69 mmHg; p=0.002 respectively). There were insufficient data to perform a meta-analysis of other cardiovascular effects. However, a systematic review of the studies included suggested a consistent improvement in surrogate markers of cardiovascular disease. Overall, the use of mineralocorticoid receptor antagonists was associated with an increased serum potassium (0.23, 95% CI 0.13, 0.33 mmol/l; p<0.0001) and higher risk ratio (1.76, 95% CI 1.20, 2.57; p=0.001) of hyperkalemia. Data on long-term cardiovascular outcomes and mortality were not available in any of the trials. Conclusions: The long-term effects of mineralocorticoid receptor antagonists on cardiovascular events, mortality and safety need to be established

A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.

BackgroundRecurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC.MethodsThis exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC.ResultsThe study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged &lt;40 years (n = 137). The analysis of evaluable patients, which combined patients aged &lt;40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099).ConclusionsIn this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged &lt;40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC.Clinical trials registrationNCT01926028

A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial

BackgroundRecurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC.MethodsThis exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC.ResultsThe study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged &lt;40 years (n = 137). The analysis of evaluable patients, which combined patients aged &lt;40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099).ConclusionsIn this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged &lt;40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC.Clinical trials registrationNCT01926028